3000Background: ICOS is a costimulatory molecule expressed on the surface of activated T cells. JTX-2011 is an ICOS agonist designed to stimulate CD4 T effector (T eff) cells and deplete intratumoral T regulatory (Treg) cells. Preclinical efficacy was seen with mouse JTX-2011 monotherapy (mono) and combination (combo) with anti-PD-1 in ICOS+ tumors. Methods: Relapsed/refractory cancer pts received escalating doses of JTX-2011 mono or combo with nivo in Phase 1 (P1), and the recommended P2 dose (RP2D) in P2, based on safety, target engagement (TE), immunophenotyping and cytokines. P2 gastric (GC) and triple negative breast (TNBC) combo cohorts completed enrollment. ICOS was assessed by IHC in archival (arch) and fresh pre-treatment tumor biopsies (bx) or by flow in peripheral blood. Results: 164 pts had ≥1 dose of JTX-2011; 71 P1 (40 mono, 31 combo); 93 P2 (25 mono, 68 combo) including 7 GC mono, 24 GC and 16 TNBC combo. Pts ≥3 prior therapies: 57% GC mono, 48% GC combo, 56% TNBC combo. JTX-2011 RP2D: 0.3m...